$4.66
0.22% day before yesterday
Nasdaq, Nov 01, 09:00 pm CET
ISIN
US9216591084
Symbol
VNDA
Sector
Industry

Vanda Pharmaceuticals Inc. Stock News

Neutral
PRNewsWire
4 days ago
Conference Call and Webcast to Follow WASHINGTON , Oct. 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2024 on Wednesday, November 6, 2024, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, November 6, 2024, during which management will discuss the third quarter 2024 fi...
Neutral
PRNewsWire
20 days ago
Board Has Determined That Latest Proposal Is Not in the Best Interests of the Company or Stockholders WASHINGTON , Oct. 14, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that it received a second unsolicited, non-binding proposal from Cycle Group Holdings Ltd. ("Cycle Group") to acquire the Company for $8.00 per share in cash.
Positive
Reuters
20 days ago
UK-based Cycle Pharmaceuticals on Monday reaffirmed its offer to buy Vanda Pharmaceuticals in a deal that values the US drugmaker at $488 million, despite a regulatory setback for its stomach condition drug in September.
Neutral
Business Wire
20 days ago
BOSTON & CAMBRIDGE, England--(BUSINESS WIRE)--Cycle Pharmaceuticals Ltd (“Cycle”), a dynamic leader in developing rare disease therapies, today reaffirmed its proposal to acquire all of the issued and outstanding shares of Vanda Pharmaceuticals, Inc. (“Vanda”) (NASDAQ: VNDA) for an all-cash consideration of $8.00 per Vanda share. Cycle is making its renewed proposal public for the benefit of Va...
Neutral
The Motley Fool
about one month ago
The biotech had discouraging news to report about one of its pipeline drugs. The FDA declined to approve its application.
Negative
Invezz
about one month ago
The company has criticized the FDA for failing to hold advisory committee meetings as well as going against the FDCA.
Negative
Reuters
about 2 months ago
The U.S. Food and Drug Administration has declined to approve Vanda Pharmaceuticals' drug to treat stomach paralysis symptoms, the company said on Thursday.
Neutral
PRNewsWire
about 2 months ago
WASHINGTON , Sept. 19, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its tradipitant development program.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today